Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetRevenue - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Cartesian Therapeutics (RNAC) Receivables - Other (2020 - 2024)

Cartesian Therapeutics (RNAC) has disclosed Receivables - Other for 5 consecutive years, with $980000.0 as the latest value for Q3 2024.

  • For Q3 2024, Receivables - Other fell 47.73% year-over-year to $980000.0; the TTM value through Sep 2024 reached $980000.0, down 47.73%, while the annual FY2023 figure was $3.0 million, 5.72% down from the prior year.
  • Receivables - Other hit $980000.0 in Q3 2024 for Cartesian Therapeutics, down from $3.5 million in the prior quarter.
  • Across five years, Receivables - Other topped out at $3.5 million in Q2 2024 and bottomed at $100000.0 in Q2 2021.
  • Average Receivables - Other over 5 years is $1.7 million, with a median of $1.5 million recorded in 2020.
  • On a YoY basis, Receivables - Other climbed as much as 229.1% in 2024 and fell as far as 47.73% in 2024.
  • Cartesian Therapeutics' Receivables - Other stood at $1.0 million in 2020, then changed by 0.0% to $1.0 million in 2021, then soared by 216.2% to $3.2 million in 2022, then decreased by 5.72% to $3.0 million in 2023, then tumbled by 67.13% to $980000.0 in 2024.
  • According to Business Quant data, Receivables - Other over the past three periods came in at $980000.0, $3.5 million, and $2.4 million for Q3 2024, Q2 2024, and Q1 2024 respectively.